Document Type
Article
Publication Date
2-24-2026
Abstract
T cell engagers (TCEs) recruit T cells to the tumor microenvironment (TME) to induce antitumor immune responses. TCEs have demonstrated promising clinical responses in patients with metastatic castration-resistant prostate cancer and have advanced into phase 3 clinical trials. Here we provide an overview of the mechanisms of action of TCEs, including both CD3-targeted and CD28-targeted agents, and review the clinical development of these agents for prostate cancer. We propose a path forward for TCEs in prostate cancer, in which innovative clinical trials will facilitate a biological understanding of mechanisms of efficacy and toxicity to inform: (1) development of predictive biomarkers for patient selection; (2) rational combination strategies; and (3) targeted treatments for toxicity management, ultimately delivering broad clinical benefit for patients with lethal prostate cancer.
Recommended Citation
Subudhi, Sumit K.; Siddiqui, Bilal A.; Zarrabi, Kevin K.; Kelly, William K.; and Drake, Charles G., "The Path Forward for T Cell Engagers in Patients With Prostate Cancer" (2026). Department of Medical Oncology Faculty Papers. Paper 329.
https://jdc.jefferson.edu/medoncfp/329
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License
PubMed ID
41734994
Language
English
Included in
Biological Phenomena, Cell Phenomena, and Immunity Commons, Male Urogenital Diseases Commons, Oncology Commons
Comments
This article is the author’s final published version in Journal for immunotherapy of cancer, Volume 14, Issue 2, 202610.1136/jitc-2025-013905.
The published version is available at https://doi.org/10.1136/jitc-2025-013905. Copyright © Author(s) (or their employer(s)) 2026.